HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Section

Money

Earnings analysis, pricing strategy, and financial dynamics

CSL sinks to nine-year low on revenue warning, $5B write-down
MoneyEndpoints News ↗
CSL's stock hit its lowest price since early 2017 on Monday after it lowered its full-year revenue guidance by…
May 11, 2026
Lilly to invest extra $4.5B across Indiana manufacturing
MoneyBioPharma Dive ↗
The Indianapolis-based company expanded its spend to ensure it can meet growing demand for its weight-loss dru…
May 8, 2026
Novo Nordisk’s Wegovy pill lifts Q1 and investor confidence
MoneyBriefing
The oral Wegovy launch brought $355M in its first quarter, helping Novo beat consensus despite insulin softnes…
May 8, 2026
Odyssey raises more than $300M as biotech goes public
MoneyEndpoints News ↗
Odyssey Therapeutics pulled together $279 million from its initial public offering, the autoimmune disease dru…
May 8, 2026
Sarepta tumbles as its gene therapy sales decline further
MoneyBioPharma Dive ↗
Even though Elevidys beat Wall Street expectations, analysts expect investor focus to shift toward Sarepta's e…
May 7, 2026
Novo hikes guidance on Wegovy pill’s fast sales start
MoneyPharmaVoice ↗
Sales and profit should shrink less than originally anticipated thanks to strong momentum for its new obesity …
May 7, 2026
← Newer Page 2 Older →
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.